Blocking conformational changes in biologically active proteins holds therapeutic promise. Inspired by the susceptibility of viral entry to inhibition by synthetic peptides that block the formation of helixhelix interactions in viral envelope proteins, we developed a computational approach for predicting interacting helices. Using this approach, which combines correlated mutations analysis and Fourier transform, we designed peptides that target gp96 and clusterin, 2 secreted chaperones known to shift between inactive and active conformations. In human blood mononuclear cells, the gp96-derived peptide inhibited the production of TNF␣, IL-1␤, IL-6, and IL-8 induced by endotoxin by >80%. When injected into mice, the peptide reduced circulating levels of endotoxin-induced TNF␣, IL-6, and IFN␥ by >50%. The clusterin-derived peptide arrested proliferation of several neoplastic cell lines, and significantly enhanced the cytostatic activity of taxol in vitro and in a xenograft model of lung cancer. Also, the predicted mode of action of the active peptides was experimentally verified. Both peptides bound to their parent proteins, and their biological activity was abolished in the presence of the peptides corresponding to the counterpart helices. These data demonstrate a previously uncharacterized method for rational design of protein antagonists.
C
onformational changes in proteins have an essential role in regulating activity. Natural and synthetic molecules that modulate such changes are of considerable biological importance. Such molecules include allosteric effectors that alter the rate of enzymecatalyzed reactions (1) , molecules that shift the oligomerization equilibrium of proteins (2) , and molecules that interfere with transmembrane helix-helix associations (3) .
Conformational changes that have been extensively studied are those that take place during viral-induced membrane fusion. This process is required for the propagation of enveloped viruses, and is facilitated by viral encoded type 1 integral membrane proteins (4, 5) . Viral entry of enveloped viruses depends on a conformational change involving the formation of helix-helix interactions, i.e., 2 alpha helices that do not interact in the native (nonfusogenic) state, but do interact with each other when the protein folds into its fusion-active (fusogenic) form. Remarkably, synthetic peptides corresponding to some of these helical segments have an antiviral activity (6 -8) , of which one has been developed for the treatment of HIV-1 infection (9, 10) .
We hypothesized that such a mode of inhibition could be also applied on nonviral proteins. The aim of the present study was to develop a computational tool for the detection of intramolecular helix-helix interactions and to use this tool for detecting such interacting helices in proteins of interest. This study focuses on secreted chaperones due to their biological and therapeutic relevance (11) (12) (13) (14) , and because conformational changes are known to take place concomitantly with their activation. We chose 2 humanencoded secreted chaperones, gp96 (15) and clusterin (16, 17) , that do not share sequence similarity.
In the present study, we describe the computational method, and demonstrate both in vitro and in vivo the antiinflammatory and anticancer properties of the gp96-and clusterin-derived peptides, respectively. Also, we provide experimental validation for the predicted mode of action of the 2 peptides at the molecular level. We conclude that these modulators of conformational change serve as therapeutic agents.
Results

Prediction of Intramolecular Helix-Helix Interactions in 2 Secreted
Chaperones, gp96 and Clusterin. To predict intramolecular interactions between pairs of amino acid residues, we analyzed correlated mutations in the sequences of a target protein and its homologs and the predicted residue-residue contact scores. Although considerable progress has been reported (18) (19) (20) (21) (22) , the signal-to-noise ratio of correlated mutation analysis and predicted residue-residue contact scores remains relatively low and does not currently allow ab initio prediction of segment-segment interactions. The central concept of our in silico approach is the exploitation of the periodic nature of the contact map for helix-helix interactions, for which the corresponding periodicity should be Ϸ3.6 aa. Fig. 1A shows the experimentally-derived contact map of HIV-1 gp41 as extracted from PDB 1ENV. The helix-helix interactions can be detected by a peak in the absolute value of the Fourier transform of this contact map, when applied on the sum by rows (or separately, by columns) of the relevant 21 ϫ 21 running submatrix. Fig. 1B illustrates the Fourier transform corresponding to the sum of rows representing the interaction between two 21-mer segments centered around residues 36 and 139 of 1ENV.
Next, we applied this approach on a contact map that was predicted on the basis of correlated mutation data. Remarkably, the Fourier transform of the predicted residue-residue contact scores also exhibits a peak Ϸ3.6 (see example in Fig. S1 ). Fourier transform was previously used to detect 1D protein features, such as amphipathic helices, i.e., helices having a hydrophobic facet opposite to a hydrophilic one (23) . To the best of our knowledge, the combination of Fourier transform and contact maps, as well as the employment of ''two-dimensional'' Fourier analysis in protein structure determination, has not been reported previously. Fourier transform substantially improves the low signal-to-noise ratio that is an intrinsic feature of correlated mutation data.
We have confirmed the ability of this computational method to detect known helix-helix interactions, such as those of viral envelope proteins. We then applied the method to 2 proteins for which conformational changes are known to be required for activity (24, 25) : gp96, a heat shock protein, which is involved in the regulation of inflammatory processes (26) , and clusterin, an extracellular chaperone protein having antiapoptotic activity that often results in resistance of cancer cells to chemotherapeutic agents (27) (28) (29) (30) (31) . The extracellular levels of both proteins are elevated after various stress stimuli. For both proteins, we detected remarkable peaks in the absolute values of the Fourier transform around the expected periodicity (Fig. 2) ; thus, predicting intramolecular helix-helix interactions in gp96 and in secreted clusterin.
Biological Activity of Synthetic Peptides Corresponding to the Interacting Helices. Peptides corresponding to these helices were chemically synthesized (Table S1) , and tested for their ability to bind their target proteins. Indeed, the gp96-II peptide (CGEN-25007) bound recombinant gp96 (Fig. 3) , whereas the clusterin-I peptide (CGEN-25008) bound recombinant secreted clusterin (Fig. S2) .
Next, gp96-II was tested for its biological effects in vitro. Freshly obtained human peripheral blood mononuclear cells (PBMC) were stimulated with LPS in the presence of 6.6 M gp96-II (Fig. 4A) . A control peptide (gp96-III), corresponding to residues 490-517 of gp96, a segment that was not predicted to be involved in a helix-helix interaction by the computational method, was also synthesized and tested as a negative control. After 24 h of incubation, IL-1␤, IL-6, IL-8, and TNF␣ were reduced by 90%, and MIP-1␣ by 80% (P Ͻ 0.03 for each). The control peptide added at the same concentration was inactive in affecting cytokine production. The gp96-II peptide also inhibited TNF␣ secretion by THP1 cells stimulated with LPS (Fig. S3) .
The effect of gp96-II was also assessed in vivo: gp96-II was injected into mice i.p. followed by LPS (10 mg/kg, i.p.). After 90 min, serum was obtained and circulating TNF␣ was measured. As shown in Fig. 4B , TNF␣ was reduced by Ͼ50% (P ϭ 0.001) compared with vehicle control. In another group of mice injected with gp96-II followed by LPS, serum was obtained after 6 h, and circulating IL-6 and IFN␥ (P ϭ 0.03) were reduced by 50-55% compared with vehicle control (Fig. 4 C and D) . therapeutic agent (Fig. S4b) . For example, as little as 1 nM of clusterin-I sensitized A549 cells to suboptimal concentrations of Taxol. Also, the optimal inhibitory effect of clusterin-I in combination with Taxol (73% inhibition) was greater than the maximal effect of clusterin-I alone (48%) and of Taxol alone (50%). When applied to tumor bearing BALB/c Nu/Nu female mice treated with Taxol, clusterin-I injected s.c. at the surrounding of the tumor graft resulted in a 25-30% reduction in tumor volume when compared with the control group treated with Taxol and vehicle (Fig. S5 ).
Experimental Support for the Molecular Mode of Action. The in silico results indicate that 2 helical segments in gp96 (gp96-I and gp96-II) interact with each other (Fig. 2) . Such a scenario (Fig. 5 A and B) is supported by the experimental data ( Figs. 3 and 4; Fig. S3 ). To further characterize the mechanism of action by which gp96-II gains its biological activity, we preincubated gp96-II with a peptide corresponding to its counterpart helix (gp96-I). We predicted that the 2 peptides interact with each other; thus, reducing the effective concentration of gp96-II (Fig. 5C) . Indeed, preincubation of gp96-II with an equimolar concentration of gp96-I abolished the inhibitory effect induced by gp96-II on TNF␣ secretion by THP1 cells stimulated with LPS (Fig. 5D) . A similar effect was observed for the 2 helical segments in clusterin, clusterin-I and clusterin-II (Fig. S6) . Thus, the above observations are consistent with the predicted mode of action, in which the biological inhibitory activity of the peptides takes place on their binding to the segment corresponding to the counterpart helix within the parent protein ( Fig. 5; Fig. S6 ). These data support the existence of both an active (''close'') conformation, in which the 2 segments interact with each other, and an inactive (''open'') conformation, in which the 2 segments do not interact. This model is also supported by disorder predictors (32) that predicts the existence of a structurally disordered region between the 2 interacting helices of gp96, allowing the 2 helices to change their relative positions. These marked conformational changes can be either irreversible, as is the case in many viral envelope proteins, or reversible, where the open and close conformations coexist in equilibrium. In the latter case, the inhibitory peptide shifts the equilibrium toward the open conformation, which is the inactive one in both of our examples. Thus, the present data are consistent with a model in which the gp96-II and clusterin-I peptides block the formation of helix-helix interaction required for the active conformations of their parent proteins.
Discussion
A few methods can be considered for designing inhibitory peptides that are derived from a target protein. The most simple is a structure-based design of inhibitory peptides, in which information regarding helix-helix interactions can be extracted from PDB. Indeed, to date, atomic-resolution 3D structures are available for numerous viral envelope proteins. However, the 3D structure of most proteins is currently unknown, as is the case for the 2 interacting helix pairs described in this article. Also, major drawbacks of this experimental approach include technical challenges raised by the metastability that often characterizes one of the physiologically-relevant conformations, particularly when dealing with proteins that adopt multiple conformations. Another method, peptide walk, is time, labor, and resource intensive, and thus, not useful for high throughput proteome-wide screens. The use of limited proteolysis, as reported by Kim and coworkers (33) for HIV-1 gp41, is an excellent biochemical method, but is relevant primarily for proteins in which the interacting helices form a protease-resistant core. Thus, limited proteolysis is usually relevant only when higher order oligomers are formed. Also, limited proteolysis requires gentle handling that does not allow high throughput analysis. Whereas this study deals with peptides that block intramolecular interactions, others developed peptides that interfere with interprotein interactions. For example, peptides corresponding to surface-exposed segments (BB loops) of different TLRs were demonstrated to block their interaction with TLR adaptor proteins; thereby, interfering with the signaling events downstream to TLR activation (34) (35) (36) .
This article describes the design of synthetic peptides, derived from a helix that is predicted to interact with another (counterpart) helix in the same protein. Such a design enables blocking of a conformational change that involves the formation of a helix-helix interaction (Fig. 5 A and B) . Our approach can be viewed as a generalization of a method for inhibiting the membrane fusion activity of envelope glycoproteins of several viruses. For the purpose of designing synthetic peptides that can target proteins of different structural folds (i.e., that do not necessarily form coiledcoils) and that are not of viral origin, we developed a general computational method for predicting helix-helix interactions. The method was applied to 2 human proteins, gp96 and clusterin, for which conformational changes are critical for activity. Peptides corresponding to their interacting helices were designed and synthesized, and their effect was tested both biochemically and in cell-based assays as well as in animal models. For each parent protein, we found a peptide that binds to the protein ( Fig. 3; Fig.  S2 ), as well as inhibits its expected activity ( Fig. 4 ; for gp96, see Fig.  S3 ; for clusterin, see Figs. S4 and S5) . Also, the biological effects of the active peptides were abolished in the presence of peptides derived from the counterpart helices ( Fig. 5D; Fig. S6) ; thus, confirming the predicted mechanism of action ( Fig. 5 A-C) .
The 2 inhibitory peptides that are reported in this study demonstrate the utility of this method for the discovery of peptides that modulate protein function, and can be applied to other clinically relevant proteins. The first target protein, gp96, triggers both the innate and the adaptive arms of the immune system. For example, gp96 serves as an accessory molecule for the activation of Toll-like receptors (TLRs). TLR activation on antigen-presenting cells (APCs) induces a proinflammatory response, including cytokine production and expression of costimulatory molecules (37) . Also, gp96 regulates the activity of plasmacytoid dendritic cells via CD91 (38, 39) . The gp96 also enables specific immune responses by potentiating cross presentation of immunogenic peptides on MHC class I; thus, facilitating antigen specific activation of cytotoxic T cells (40) (41) (42) (43) . A phase II trial is ongoing, in which patients are immunized with complexes of gp96 in combination with tumor antigens to promote presentation of these tumor-derived antigens by APC (44) . Here, we show that when incubated with LPS-stimulated PBMC, gp96-II caused a marked reduction in the secretion of several proinflammatory cytokines (Fig. 4A) . This finding is consistent with reports that gp96 functions as a TLR accessory molecule (15) .
Intraperitoneal injection of gp96-II into C57Black/6 mice just before LPS administration significantly reduced the circulating levels of TNF␣, IL-6, and IFN␥ (Fig. 4 B-D) . Also, we were able to observe that mice treated with gp96-II exhibited a reduction in the appearance of the shock-like state. The mice exhibited normal movements compared with the saline-LPS group. Although the reduction in the levels of TNF␣ and IL-6 is likely a result of a direct effect of the peptide on LPSstimulated monocytes/macrophages, the reduction in circulating IFN␥ is likely mediated by the reduction in IL-12 and IL-18 levels or the ability of IL-12 plus IL-18 to induce IFN␥.
The second target protein, clusterin, is a stress-associated cytoprotective chaperone (45) . This protein, which is upregulated by activators of apoptosis, confers resistance to chemotherapeutic agents in neoplastic cells. Among the stress signals that cause up-regulation of clusterin are chemotherapy, irradiation, and hormone ablation (28, 30, 31, 46 -49) . A clusterin-inhibiting antisense oligonucleotide has been reported as a potential treatment for increasing the susceptibility of solid tumors to conventional cancer therapies (50, 51) . Here, we demonstrate that clusterin-I, designed as an antagonist of clusterin, has anticancer effect in vitro (Fig. S4) , as well as in vivo (Fig. S5) . The combination of clusterin-I and chemotherapeutic drugs might achieve similar anticancer activity with lower doses of chemotherapy; thus, reducing side effects. Also, treatment with the combination of Taxol and clusterin-I may achieve a better antineoplastic effect compared with monotherapy.
The susceptibility of a protein to inhibition by peptides should not be automatically assumed, because the native conformation of the protein might not be available to inhibition. Alternatively, inhibition can take place only in an intermediate conformation, and in such cases, efficient inhibition can occur only if this intermediate state exists for sufficient time. For example, despite the structural resemblance between the envelope glycoproteins of HIV-1 and the inf luenza virus, there are no peptidic fusion inhibitors for the latter virus, probably because after a few milliseconds, the fusion process induced by the inf luenza virus is completed (52) . In contrast, HIV-1 requires Ϸ1 h for fusion, which is sufficient for binding of inhibitors (53) . Biochemical evidence suggests the existence of intermediate conformational states of both gp96 (54) and clusterin (55) , and although there are no data presently available on the lifetime of these intermediate states, the data presented here suggest that there is sufficient time to allow for inhibition.
Whereas peptides corresponding to 1 helix exhibit biological activity, the peptides corresponding to the counterpart helix do not. The lack of activity of the peptides corresponding to the counterpart helix may be due to unfavorable stoichiometry, as demonstrated in the case of the HIV-1 gp41-derived peptides (56) . Second, nonoptimal sequence of the counterpart helix. As revealed in many cases, addition or deletion of a few amino acid residues to/from the N or C terminus of a peptide may cause dramatic reductions in the activity (6, 8, 56, 57) .
The method described here can be applied to the development of reagents other than peptides. For example, antibodies that bind to the counterpart helix are likely to be highly effective. In fact, neutralizing antibodies from a survivor of Ebola virus infection block the conformational changes of the Ebola virus glycoprotein (58) , and antibodies to the HIV-1 gp120 blocked this protein in its preactive conformation (59) .
In summary, the computational method described in this article is innovative in the field of protein structure prediction. Also, this method may allow for the development of novel therapeutic peptides for a broad range of clinical indications. 
Materials and Methods
In silico prediction of helix-helix interactions was achieved by analyzing the periodicities in predicted residue-residue contact maps as detailed in the SI Materials and Methods. Briefly, predicted contact maps of gp96 and secreted clusterin were calculated using SVMcon (19). These contact maps were then analyzed using Fourier transform to reveal the 3.6 periodicities that are typical of helix-helix interactions.
For experimental confirmation of the in silico prediction, peptides corresponding to the predicted interacting helices were synthesized and tested for biological activity. Biochemical binding of the peptides to their parent protein was tested using surface plasmon resonance. Also, functional characterizations, as well as mode of action studies, were performed both in vitro and in vivo. For more details, see SI Materials and Methods.
